2seventy bio
2seventy bio was an immuno-oncology cell therapy company, spun out of Bluebird bio in 2021, that developed and commercialized ABECMA, a BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma, in partnership with Bristol Myers Squibb before being acquired by BMS in March 2025.
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What 2seventy bio does
2seventy bio was an immuno-oncology cell therapy company founded in 2021 as a spinout of Bluebird bio, headquartered in Cambridge, Massachusetts. The company discovered, developed, and commercialized autologous CAR-T cell therapies, with its lead and sole commercial product being ABECMA (idecabtagene vicleucel), a BCMA-directed CAR-T therapy for adults with relapsed or refractory multiple myeloma. ABECMA is manufactured using a proprietary process that engineers each patient's own T cells to target BCMA-expressing cells, with a one-time treatment model positioned as a potentially durable option for patients who have exhausted prior lines of therapy. ABECMA generated $406 million in sales in 2024 per the input data, marketed in partnership with Bristol Myers Squibb.
2seventy bio operated a partner-led commercial model: BMS provided the specialty distribution infrastructure, certified treatment center network, and field sales organization that marketed ABECMA to hematologists and oncology centers globally, while 2seventy bio contributed the cell therapy platform, manufacturing expertise, and clinical development. Revenue was generated through a combination of ABECMA product economics shared with BMS and contractual milestones, with cell therapies in this category typically priced at $400,000-$500,000 per patient. The company supplemented ABECMA with early-stage pipeline assets, notably bbT369, a CAR-T candidate for lymphoma that was sold to Regeneron in January 2024 for $5 million.
The company was financed primarily through a $170 million private placement in March 2022 led by a syndicate of healthcare-specialist investors including Bain Capital Life Sciences, EcoR1 Capital, Janus Henderson, and RTW Investments. Over its standalone life, 2seventy bio narrowed its scope to a single commercial asset and was acquired by Bristol Myers Squibb in March 2025 for approximately $286 million, with BMS taking full control of ABECMA and the underlying cell therapy platform.
2seventy bio firmographics
Firmographics- Name
- 2seventy bio
- Legal name
- 2seventy bio, Inc.
- Website
- https://2seventybio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- 2seventy bio was an immuno-oncology cell therapy company, spun out of Bluebird bio in 2021, that developed and commercialized ABECMA, a BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma, in partnership with Bristol Myers Squibb before being acquired by BMS in March 2025.
- Ownership category
- akta.pro rank
2seventy bio industry classification
Industry- Product category
- Cell Therapy Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
Keywords
Where 2seventy bio is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
2seventy bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Product Sales - ABECMA: Revenue from commercialization of ABECMA (idecabtagene vicleucel), a CAR-T cell therapy for multiple myeloma, marketed in collaboration with Bristol Myers Squibb
- BMS Acquisition Proceeds: 2seventy bio was acquired by Bristol Myers Squibb for approximately $286 million in 2025, gaining full control of ABECMA
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
2seventy bio product offering
Product offeringCore offering
2seventy bio is an immuno-oncology cell therapy company that discovers, develops, and commercializes autologous CAR-T cell therapies. Its flagship commercial product, ABECMA (idecabtagene vicleucel), is a BCMA-directed CAR-T cell therapy approved for adult patients with relapsed or refractory multiple myeloma, marketed in collaboration with Bristol Myers Squibb. The company was founded in 2021 as a spinout from Bluebird bio and was acquired by Bristol Myers Squibb in March 2025.
Product overview
2seventy bio was a biotech company specializing in cell therapy products, particularly CAR-T (chimeric antigen receptor T-cell) therapies. The company was a spinout of Bluebird bio and operated as a focused cell therapy company. Their primary product was ABECMA, a CAR-T therapy for multiple myeloma marketed in partnership with Bristol Myers Squibb. The company also had pipeline assets including bbT369 for lymphoma, which was sold to Regeneron. In March 2025, Bristol Myers Squibb acquired 2seventy bio for approximately $286 million to take full control of ABECMA.
Differentiator
Problem solved
Functional benefit
Products and services
- ABECMA (idecabtagene vicleucel)
Quantifiable outcome
- ABECMA generated $406 million in sales in 2024
Companies that use 2seventy bio
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
2seventy bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
2seventy bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Bristol Myers SquibbcoreBMS was the primary strategic partner for 2seventy bio, co-developing and commercializing ABECMA. BMS acquired 2seventy bio in 2025 for $286 million to take full control of the cell therapy. The partnership included manufacturing capacity expansion to meet rising demand for ABECMA.
- Johnson & Johnson/Legend BiotechminorPatent litigation dispute over CAR-T cell therapy intellectual property. 2seventy bio (BMS-backed) filed lawsuit at the Unified Patent Court against J&J/Legend Biotech over patent rights to Carvykti for multiple myeloma treatment.
Scale indicators5 records
Recent moves7 records
Expansion highlights4 records
2seventy bio competitors and assessment
Company assessmentBroad incumbents
- Bristol Myers Squibb: Global biopharma that co-developed and ultimately acquired 2seventy bio for $286M in 2025. Direct commercialization partner for ABECMA and now owner of the cell therapy franchise; comparable as the integrated incumbent in the same CAR-T commercial value chain.
- Johnson & Johnson: Co-markets Carvykti (BCMA CAR-T for multiple myeloma) with Legend Biotech, the principal direct competitor to ABECMA. Comparable as a large biopharma commercializing an autologous CAR-T therapy in the same indication via a similar specialty treatment-center channel.
- Novartis: Marketer of Kymriah, the first FDA-approved CAR-T cell therapy. Comparable as an established biopharma operating a commercial autologous CAR-T franchise (hematologic malignancies) and competing in the broader cell therapy commercial landscape that 2seventy participates in.
- Gilead Sciences (Kite Pharma): Through Kite Pharma, commercializes Yescarta and Tecartus — leading autologous CAR-T therapies in B-cell malignancies. Comparable as a major incumbent in the autologous CAR-T commercial market with established manufacturing and hospital-channel infrastructure similar to what 2seventy leveraged via BMS.
Direct peers
- Legend Biotech: Co-developer with J&J of Carvykti, a BCMA-directed autologous CAR-T cell therapy for multiple myeloma. Closest direct peer to 2seventy bio — same modality (autologous CAR-T), same target (BCMA), same indication (multiple myeloma), and the named defendant in 2seventy/BMS's patent litigation.
- bluebird bio: Original parent of 2seventy bio; spun out the cell therapy division (ABECMA-related assets and team) in 2021. Comparable as a gene and cell therapy company with overlapping scientific lineage, manufacturing know-how, and the same multiple myeloma patient focus.
Emerging players
- Allogene Therapeutics: Clinical-stage developer of allogeneic ("off-the-shelf") CAR-T cell therapies. Comparable as a cell therapy company targeting hematologic cancers with an engineered T-cell platform, representing the next-generation architectural alternative to 2seventy's autologous approach.
- Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies for hematologic malignancies. Comparable as a peer cell therapy developer operating in the same engineered T-cell therapy category with overlapping target indications.
- CRISPR Therapeutics: Developer of gene-edited cell therapies including allogeneic CAR-T candidates for hematologic cancers. Comparable as a next-generation cell therapy company using novel manufacturing/engineering approaches that could pressure autologous CAR-T incumbents like 2seventy bio.
Others
- Regeneron: Acquired 2seventy's bbT369 lymphoma CAR-T candidate in January 2024 (later discontinued). Comparable as a biopharma actively investing in cell therapy R&D, and relevant as the acquirer of divested 2seventy pipeline assets — a signal of the standalone pipeline's limited perceived value.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
2seventy bio social profiles
Digital presence2seventy bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
2seventy bio leadership team
Management profileNumber of profiles
Profiles8 records
2seventy bio subsidiaries and ownership
Company hierarchySubsidiaries1 record
2seventy bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
2seventy bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 2seventy bio
What does 2seventy bio do?
2seventy bio is an immuno-oncology cell therapy company that discovers, develops, and commercializes autologous CAR-T cell therapies. Its flagship commercial product, ABECMA (idecabtagene vicleucel), is a BCMA-directed CAR-T cell therapy approved for adult patients with relapsed or refractory multiple myeloma, marketed in collaboration with Bristol Myers Squibb. The company was founded in 2021 as a spinout from Bluebird bio and was acquired by Bristol Myers Squibb in March 2025.
Is 2seventy bio a public or private company?
2seventy bio is a private company. It is classified as public and is currently acquired.
When was 2seventy bio founded?
2seventy bio was founded in 2021. It employs 501 to 1,000 people.
Where is 2seventy bio based?
2seventy bio is headquartered in Cambridge, United States, in the North America region.
How does 2seventy bio make money?
Two revenue lines are on record. Product Sales - ABECMA is the primary driver. The others are BMS Acquisition Proceeds.
Who are 2seventy bio's main competitors?
Broad incumbents on record are Bristol Myers Squibb, Johnson & Johnson, Novartis and Gilead Sciences (Kite Pharma). Direct peers are Legend Biotech and bluebird bio. Emerging players are Allogene Therapeutics, Caribou Biosciences and CRISPR Therapeutics. Regeneron is listed as an others.
Does 2seventy bio have an API?
No public API is recorded for 2seventy bio.
What industry is 2seventy bio in?
2seventy bio's product category is Cell Therapy Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2836.